5DZL

Crystal structure of the protein human CEACAM1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.4006 Å
  • R-Value Free: 0.288 
  • R-Value Work: 0.232 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Huang, Y.H.Zhu, C.Kondo, Y.Anderson, A.C.Gandhi, A.Russell, A.Dougan, S.K.Petersen, B.S.Melum, E.Pertel, T.Clayton, K.L.Raab, M.Chen, Q.Beauchemin, N.Yazaki, P.J.Pyzik, M.Ostrowski, M.A.Glickman, J.N.Rudd, C.E.Ploegh, H.L.Franke, A.Petsko, G.A.Kuchroo, V.K.Blumberg, R.S.

(2015) Nature 517: 386-390

  • DOI: 10.1038/nature13848
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM- ...

    T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.


    Organizational Affiliation

    Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Carcinoembryonic antigen-related cell adhesion molecule 1
A, B, C, D
108Homo sapiensMutation(s): 0 
Gene Names: CEACAM1 (BGP, BGP1)
Find proteins for P13688 (Homo sapiens)
Go to Gene View: CEACAM1
Go to UniProtKB:  P13688
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.4006 Å
  • R-Value Free: 0.288 
  • R-Value Work: 0.232 
  • Space Group: P 41 21 2
Unit Cell:
Length (Å)Angle (°)
a = 75.760α = 90.00
b = 75.760β = 90.00
c = 147.420γ = 90.00
Software Package:
Software NamePurpose
PHENIXrefinement
PDB_EXTRACTdata extraction
MOLREPphasing
Aimlessdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2015-10-07
    Type: Initial release
  • Version 1.1: 2015-10-14
    Type: Structure summary
  • Version 1.2: 2017-11-22
    Type: Derived calculations, Refinement description